These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352 [TBL] [Abstract][Full Text] [Related]
12. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822 [TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358 [TBL] [Abstract][Full Text] [Related]
15. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779 [TBL] [Abstract][Full Text] [Related]
16. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266 [TBL] [Abstract][Full Text] [Related]
17. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors. Crawford Y; Ferrara N Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058 [TBL] [Abstract][Full Text] [Related]
18. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Hicklin DJ; Ellis LM J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754 [TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth. Ghosh S; Maity P Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827 [TBL] [Abstract][Full Text] [Related]
20. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Leite de Oliveira R; Hamm A; Mazzone M Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]